Streetbeat News

Price Targets

GWW

Jefferies analyst Hamzah Mazari has downgraded W.W. Grainger (NYSE:GWW) from Buy to Hold and set a price target of $825.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:49 pm

TEX

Jefferies analyst Stephen Volkmann has downgraded Terex Corporation (NYSE:TEX) from Buy to Hold and reduced the price target from $73 to $63.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:47 pm

TKR

Jefferies analyst Stephen Volkmann has downgraded Timken (NYSE:TKR) from Buy to Hold and reduced the price target from $105 to $85.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:33 pm

ENS

Oppenheimer analyst Noah Kaye has maintained an Outperform rating on EnerSys (NYSE:ENS) and increased the price target from $110 to $116, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:22 pm

UTI

Rosenblatt analyst Steve Frankel has reiterated a Buy rating on Universal Technical Institute (NYSE:UTI) and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:16 pm

FDX

Barclays analyst Brandon Oglenski has maintained an Overweight rating on FedEx (NYSE:FDX) but reduced the price target from $330 to $310.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:10 pm

BCYC

JMP Securities analyst Reni Benjamin has maintained a Market Outperform rating on Bicycle Therapeutics (NASDAQ:BCYC) but has reduced the price target from $44 to $32.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:06 pm

FND

Floor & Decor Holdings (NYSE:FND) has received mixed analyst ratings over the past quarter, with 14 analysts offering diverse opinions. The average 12-month price target is now $91.86, down 11.67% from the previous $104.00. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. The company operates in the hard surface flooring market and has shown strong revenue growth and net margin, but its ROE is below industry average. Its debt-to-equity ratio is favorable compared to the industry.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:01 pm

MRTX

Mirati Therapeutics (NASDAQ:MRTX) has received mixed analyst ratings over the past quarter, with 11 analysts offering diverse opinions. The average 12-month price target for MRTX is $64.09, with a high estimate of $83.00 and a low of $58.00, reflecting a 7.34% increase from the previous target of $59.71. Analysts from Citigroup, Leerink Partners, Stifel, Piper Sandler, B. Riley Securities, Scotiabank, Jefferies, BMO Capital, and JMP Securities have adjusted their ratings and price targets, indicating a range of expectations for the company's performance. Mirati Therapeutics, a clinical-stage oncology company, has shown a revenue growth rate of 201.97% as of September 30, 2023, but struggles with a net margin of -987.22% and an ROA of -15.84%, despite a strong ROE of -19.33% and a low debt-to-equity ratio of 0.05.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:00 pm

PCRX

Pacira BioSciences (NASDAQ:PCRX) was analyzed by 7 analysts, showing a mix of bullish and somewhat bullish ratings, with no bearish or indifferent stances. The average 12-month price target is $52.71, down from $58.40. Analysts from firms like Raymond James, HC Wainwright & Co., Piper Sandler, RBC Capital, Needham, and Barclays have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Pacira BioSciences, known for its non-opioid pain management solutions, has seen a -2.11% revenue decline as of September 30, 2023, but outperforms in net margin and ROE, with a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:00 pm